Literature DB >> 8470644

Acetaminophen hepatotoxicity: potentiation by isoniazid.

J S Crippin1.   

Abstract

Potentiation of acetaminophen hepatotoxicity has previously been associated with a history of alcohol abuse. Presented here is the case of a 21-yr-old Philippino female with rapidly deteriorating hepatic functions. She had been on isoniazid, 300 mg daily, as prophylaxis against tuberculosis due to a positive tuberculin skin test. She took 3.25 g of acetaminophen for abdominal cramping and subsequently had rapid deterioration of liver function manifested by prolongation of the prothrombin time, elevated ammonia, marked elevation of transaminases, and hyperbilirubinemia. Over the course of 1 wk, these values essentially normalized and she was discharged. Isoniazid induces the cytochrome P-450 system, resulting in increased metabolism of acetaminophen, formation of toxic metabolites, depletion of glutathione stores, and subsequent hepatocellular injury. Patients on isoniazid should use caution when taking acetaminophen since the potentially hepatotoxic effects may be amplified due to induction of the cytochrome P-450 system.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8470644

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  15 in total

Review 1.  [Cytochrom-P450 mediated drug interactions caused by antibiotics].

Authors:  Christiane Thallinger; Christian Joukhadar
Journal:  Wien Med Wochenschr       Date:  2006-09

Review 2.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

3.  PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses.

Authors:  Liudmila L Mazaleuskaya; Katrin Sangkuhl; Caroline F Thorn; Garret A FitzGerald; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-08       Impact factor: 2.089

4.  Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A.

Authors:  Z Desta; N V Soukhova; D A Flockhart
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 5.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 6.  Paracetamol, alcohol and the liver.

Authors:  L F Prescott
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

Review 7.  Hepatotoxic effects of therapies for tuberculosis.

Authors:  Bahaa E Senousy; Sanaa I Belal; Peter V Draganov
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-08-31       Impact factor: 46.802

Review 8.  PXR antagonists and implication in drug metabolism.

Authors:  Sridhar Mani; Wei Dou; Matthew R Redinbo
Journal:  Drug Metab Rev       Date:  2013-02       Impact factor: 4.518

Review 9.  The pregnane X receptor: from bench to bedside.

Authors:  Xiaochao Ma; Jeffrey R Idle; Frank J Gonzalez
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-07       Impact factor: 4.481

Review 10.  Management of paracetamol overdose: current controversies.

Authors:  E Kozer; G Koren
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.